Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

VTT Develops Piglet Vaccination To Reduce Antibiotics Use

By VTT Technical Research Centre of Finland Ltd. | July 5, 2018

The VTT Technical Research Centre of Finland has developed a vaccine, diluted into drinking water, to treat diarrhea in piglets being weaned. The vaccine reduces the global resistance problem caused by excessive antibiotic use.

The vaccine is a new type of product that can replace antimicrobial drugs, such as zinc oxide, used is pig production. Bacterial strains resistant to antibiotics have become a global health threat. Bacteria do not know any boundaries, so this also is a problem for Finland, although Finland uses antibiotics in moderation when treating farm animals.

“The vaccine’s production method has proved to be very effective, and it can also be used in the development of other animal vaccines. The method may be available commercially already in the next few years,” says Jussi Joensuu, principal scientist of VTT.

Before that, however, it must be shown in practice that the vaccine is effective and safe. The first animal test was carried out this summer in Belgium, and the results in terms of efficiency are promising.

“When administered in drinking water, the vaccine offers protection exactly where it is needed, namely in the intestine. If the vaccine was injected, most of the antibodies would remain in the bloodstream,” says Joensuu.

When still suckling, piglets get enough protection from the sow’s milk. The disease emerges when piglets go from liquids to solids, enabling harmful bacteria—usually E. coli—to attach to the intestine. At this stage, the piglet’s own antibody production is only starting, and pathogenic bacteria get a foothold in the small intestine leading to diarrhea.

The piglet suffers, its growth slows down and in extreme cases, the diarrhea causes death. Piglet scour is estimated to cause annual losses of €1-2 billion ($1.2-2.3 billion) globally.

The vaccine is administered to piglets in drinking water after weaning. The piglet’s immune system will recognize the vaccine molecule and start creating antibodies against the bacteria. The antibodies will prevent bacteria from attaching to the receptors in the small intestine, thereby preventing diarrhea.

Currently porcine post weaning diarrhea is prevented by means of, for example, diet, hygienic rearing conditions, and antibiotics. Globally speaking, up to 70 percent of antibiotics are used on animals, especially farm animals.

Filamentous Fungus as the Expression System

The background for this development lies in Joensuu’s dissertation in 2006 in which he proved the effectiveness of the vaccine molecule. At that time the idea was to produce the vaccine molecules in transgenic plants, but the method was not commercially viable.

The expression system chosen by VTT was filamentous fungus Trichoderma reesei. The vaccine is produced by means of a fermentation process in a closed bioreactor.

Resistance to Antibiotics Is a Serious Health Threat

According to the World Health Organization, resistance to antibiotics is a global health threat. This means that antibiotics no longer have the same effectiveness. This increases human and animal illness and mortality and increases health care costs. Resistance to antibiotics has become one of the most serious threats to medicine and veterinary medicine.

(Source: VTT Technical Research Centre of Finland)


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE